Frederick Nahas v. Shore Medical Center

Court of Appeals for the Third Circuit·Decided September 18, 2020·No. 19-3433·Unpublished

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

No. 19-3433

FREDERICK NAHAS, M.D.,

Appellant

v.

SHORE MEDICAL CENTER; STEVEN P. NACHTIGALL;

JEFFREY GOSIN; PEYTON DEARBORN; PETER JUNGBLUT;

MEDICAL EXECUTIVE COMMITTEE; LEONARD GALLER

On Appeal from the United States District Court for the District of New Jersey (D.C. No. 1-13-cv-06537)

Honorable Robert B. Kugler, U.S. District Judge

Submitted Under Third Circuit L.A.R. 34.1(a)

on September 17, 2020

Before: KRAUSE, RESTREPO, and BIBAS, Circuit Judges

(Opinion filed: September 18, 2020)

OPINION *

*

This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not constitute binding precedent.

KRAUSE, Circuit Judge.

Frederick Nahas appeals the District Court’s summary judgment in favor of his employer, Shore Medical Center, its Medical Executive Committee, and various medical officers (collectively Shore Medical), on his claims under Section 1 of the Sherman Antitrust Act, 15 U.S.C. § 1, and 42 U.S.C. § 1981, as well as the dismissal of his breach of contract claim under state law. For the reasons that follow, we will affirm. A. Discussion 1 On appeal, Nahas contends first, that the District Court erred in rejecting his antitrust claim for lack of standing; second, that the denial of his privileges by Shore Medical constituted race discrimination; and third, that the District Court erred in dismissing his breach of contract claim for lack of subject matter jurisdiction. We address each argument below. 2 1. Nahas’s Sherman Act Claim Where a private plaintiff asserts an antitrust claim, we require that, in addition to Article III standing, he demonstrate “antitrust standing” to sue. While not jurisdictional, that inquiry “focus[es] on the nature of the plaintiff’s alleged injury” and asks “whether it is of

the type that the antitrust statute was intended to forestall.” Hartig Drug Co. v. Senju Pharm. Co., 836 F.3d 261, 269 (3d Cir. 2016) (quoting Associated Gen. Contractors of Cal. v. Cal. State Council of Carpenters, 459 U.S. 519, 538, 540 (1983)) (internal quotation marks omitted); see Ethypharm S.A. Fr. v. Abbott Labs., 707 F.3d 223, 232 (3d Cir. 2013) (citing City of Pittsburgh v. W. Penn. Power Co., 147 F.3d 256, 264 (3d Cir. 1998)).

To establish antitrust injury a plaintiff must show that the injury “reflect[s] the anticompetitive effect either of the violation or of anticompetitive acts made possible by the violation,” Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc., 429 U.S. 477, 489 (1977), or, put differently, that the “challenged conduct affected the prices, quantity or quality of goods or services” available or had a competition-reducing effect beyond the plaintiff’s “own welfare.” Mathews v. Lancaster Gen. Hosp., 87 F.3d 624, 641 (3d Cir. 1996) (quoting Tunis Bros. Co. v. Ford Motor Co., 952 F.2d 715, 728 (3d Cir. 1991)). In the context of a denial of physician privileges, in particular, we have held that unless the restriction significantly reduces the services available to patients in the area or “completely extinguish[es] [the practitioner’s] ability to provide . . . services,” it does not constitute an antitrust injury. Id.

Applying these principles here, it is clear that Nahas failed to make the requisite showing. Nahas argues that Shore Medical’s denial of his application prevented him from participating in the relevant market, thereby placing him at a competitive disadvantage. Specifically, he asserts that he was unable to provide certain services to his hospitalized patients and that seeking privileges elsewhere would disrupt his patient referral patterns, and he points us to expert reports finding that the economic reality of the market makes

pursuing any alternatives potentially harmful to his practice. From this he suggests he suffered “the type [of injury] that the antitrust statute was intended to forestall.” Hartig Drug Co., 836 F.3d at 269.

We are not persuaded. Though he complains about the limitation placed by Shore Medical on his ability to practice, that is not an injury that “affected the prices, quantity or quality of goods or services” available to consumers or that had an anticompetitive effect beyond Nahas’s “own welfare.” Mathews, 87 F.3d at 641. Not only does Nahas retain general and vascular surgery privileges at Shore Medical, but he also has unrestricted endovascular privileges at a nearby facility and is capable of applying for similar privileges elsewhere. The restriction of Nahas’s endovascular privileges thus does not “completely extinguish [his] ability to provide . . . services” and bar him from the relevant market, nor does it deny patients access to services as consumers. Id.

Even drawing “[a]ll reasonable inferences . . . in favor of the nonmoving party,” as we must on summary judgment, there was insufficient evidence of an antitrust injury. Goldenstein v. Repossessors Inc., 815 F.3d 142, 146 (3d Cir. 2016) (internal quotation marks omitted); see Fed. R. Civ. P. 56(a). The District Court therefore did not err in concluding Shore Medical was entitled to judgment as a matter of law.

2. Nahas’s § 1981 Claim We analyze Nahas’s § 1981 claim for race discrimination under the familiar burden-

shifting framework of McDonnell Douglas Corp. v. Green, 411 U.S. 792, 802 (1973): first, the plaintiff must establish “a prima facie case of . . . discrimination,” id.; if he succeeds, “[t]he burden then must shift to the employer to articulate some legitimate,

nondiscriminatory reason for the employee’s rejection,” id.; and if the employer meets its burden, the plaintiff must show that the “stated reason[s] for [his] rejection [were] in fact pretext” for discrimination, id. at 804.

The dispute here centers on this third step.3 To establish pretext at summary judgment, a plaintiff must provide evidence that “1) casts sufficient doubt upon . . . [the] reasons proffered . . . so that a factfinder could reasonably conclude that each reason was a fabrication” or “2) allows the factfinder to infer that discrimination was more likely than not a motivating or determinative cause of the adverse employment action.” Fuentes v. Perskie, 32 F.3d 759, 762 (3d Cir. 1994). Such evidence may include preferential treatment of other employees who are similarly situated. See McDonnell Douglas, 411 U.S. at 804.

As evidence that Shore Medical’s proffered reasons satisfy these conditions, Nahas asserts that the application criteria were applied unequally and that he was “objectively more qualified” than the candidate conditionally approved. Appellant’s Br. 52. He focuses, in particular, on the supervision requirement as “a classic post hoc fabrication” applied strictly to him and not others, Appellant’s Br. 54, and while he does not dispute his own failure to satisfy it, he takes issue with Shore Medical’s grant of privileges to a non- Arab candidate who had not yet completed that requirement and who allegedly possessed

far less medical experience than Nahas. According to Nahas, that disparate treatment, in “relax[ing] [the] qualifications for one candidate” by accepting that candidate prior to his fulfillment of the supervision requirement, reveals pretext. Appellant’s Br. 53.

Free access — add to your briefcase to read the full text and ask questions with AI

Frederick Nahas v. Shore Medical Center, (3d Cir. 2020).

Frederick Nahas v. Shore Medical Center (Frederick Nahas v. Shore Medical Center) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc.
429 U.S. 477 (Supreme Court, 1977)
Hedges v. Musco
204 F.3d 109 (Third Circuit, 2000)
Ethypharm S.A. France v. Abbott Laboratories
707 F.3d 223 (Third Circuit, 2013)
Kirleis v. Dickie, McCamey & Chilcote, P.C.
560 F.3d 156 (Third Circuit, 2009)
Frederico v. Home Depot
507 F.3d 188 (Third Circuit, 2007)
Matthew Faush v. Tuesday Morning
808 F.3d 208 (Third Circuit, 2015)
Heiko Goldenstein v. Repossessors Inc.
815 F.3d 142 (Third Circuit, 2016)
Hartig Drug Co Inc v. Senju Pharmaceutical Co Ltd
836 F.3d 261 (Third Circuit, 2016)
Tribune Media Company v.
902 F.3d 384 (Third Circuit, 2018)
North Sound Capital LLC v. Merck & Co Inc
938 F.3d 482 (Third Circuit, 2019)
Tunis Bros. v. Ford Motor Co.
952 F.2d 715 (Third Circuit, 1991)